Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Muscular Dystrophy Association Convenes Regulatory, Clinical and Scientific Leaders to Showcase Latest Progress in the Field of Neuromuscular Disease on April 16, 2019 at 12:18 pm
Experts shared insights from across the spectrum of neuromuscular diseases including Duchenne muscular dystrophy (DMD), spinal muscular dystrophy (SMA) and amyotrophic lateral sclerosis (ALS). […]
- PREVIEW: United With Differences on April 16, 2019 at 10:59 am
An, a fourth-year business administration student, was born with a disease called Duchenne Muscular Dystrophy (DMD), which destroys muscles and reduces life span. An and his team have been planning ... […]
- Wave Life Sci presents final safety data on DMD candidate suvodirsen; shares down 11% premarket on April 16, 2019 at 5:27 am
Wave Life Sciences (NASDAQ:WVE) slips 11% premarket on light volume on the heels of final safety and tolerability data on Duchenne muscular dystrophy (DMD) candidate suvodirsen (WVE-210201 ... […]
- Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design on April 16, 2019 at 4:00 am
Following the webcast, a replay will be available on the website. About Duchenne Muscular Dystrophy Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic neuromuscular disorder caused ... […]
- FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy on April 15, 2019 at 8:06 pm
SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced ... […]
- Pamrevlumab Gets Orphan Drug Designation for Duchenne Muscular Dystrophy on April 15, 2019 at 11:28 am
The Food and Drug Administration (FDA) has granted Orphan Drug designation to pamrevlumab (FibroGen), for the treatment of patients with Duchenne muscular dystrophy (DMD). Pamrevlumab is a ... […]
- Santhera to Present Long-term Efficacy Results with Idebenone in DMD at the 2019 MDA Clinical and Scientific Conference on April 14, 2019 at 10:44 pm
Pratteln, Switzerland, April 15, 2019 - Santhera Pharmaceuticals (SIX: SANN) and its collaborating clinical experts present results of long-term efficacy on respiratory function outcomes in ... […]
- Global $1.02 Bn Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecasts to 2028 on April 12, 2019 at 1:07 pm
DUBLIN, April 12, 2019 /PRNewswire/ -- The "Duchenne Muscular Dystrophy - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering. […]
- Family creates scholarship after dedicated Clemson fan with muscular dystrophy passes away on April 11, 2019 at 10:35 am
BRAINTREE, MA (FOX Carolina) - Jake Parker lived an extraordinary life. Despite living with Duchenne Muscular Dystrophy, the fourteen year old had a passion for living, for traveling, and for rooting ... […]
- Duchenne Muscular Dystrophy (DMD) Market: Rising Demand for Effective Therapies Among Patients to Drive the Market on April 10, 2019 at 3:06 am
Albany, NY -- (SBWIRE) -- 04/10/2019 -- Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by muscle degeneration and weakness. Duchenne muscular dystrophy (DMD) cause due to lack ... […]
via Bing News